

IV Incontro SYRP: S.I.Fit. Young Researchers Project Giovani Ricercatori in Fitoterapia



EFFECTS OF DIPLACONE AND CUDRAFLAVONE B ON GASTROINTESTINAL MOTILITY

Silvia Cerantola^{1,2}, Zora Vochyánová³, Ilaria Marsilio¹, Valentina Caputi¹, Isabella Lante², Jan Hošek³, Maria Cecilia Giron¹

¹Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Italy; ²San Camillo Hospital, Treviso, Italy; ³Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Czech Republic

BACKGROUND

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder with high social and economic impact, characterized by abnormal gut motor function, enhanced visceral perception, abnormalities in central pain processing and neurochemical coding, and altered gut microbiota, besides psychosocial and genetic factors (De Palma et al., 2014). The etiology remains unclear and there is no causal treatment. The only available therapy have purely symptomatic effects and only limited efficacy. Several studies have shown the anti-inflammatory and antioxidant effects of flavonoids, making them potential candidates for treating inflammatory processes (Vochyanova et al., 2015). Recently, diplacone, a geranylated flavanone, has been shown to ameliorate dextran sulfate sodium-induced colitis in rats (Vochyanova et al., 2015) whereas cudraflavone B, a prenylated flavonoid, has been shown to exert anti-inflammatory and neuroprotective effects (Lee et al., 2014; Zelova et al., 2014).

CONCLUSION

Our study provides evidence that flavonoids, such as diplacone and cudraflavone B:

- influence enteric motor function;
- have potential clinical interest for treating intestinal dysmotility associated to IBS.

To evaluate the effects of diplacone and cudraflavone B on gastrointestinal neuromuscular function.

RESULTS

EFFECTS OF CUDRAFLAVONE B ON INTESTINAL MOTILITY



Figure 1. Impaired gastrointestinal transit in mice treated with cudraflavone B.

Panel A. Gastrointestinal (GI) transit was measured as % of nonabsorbable FITC-dextran distribution in 15 gut segments, comprising stomach (Sto), small intestine (Sb 1–10), cecum (Cec) and colon (Col 1–3), 30 minutes after oral administration in SHAM and CUDRA mice (N = 3). Panel B. Analysis of Geometric center (GC) demonstrated a significant alteration of GI transit in CUDRA mice compared to SHAM mice (GC_{CUDRA}= 9.4±0.2 vs GC_{SHAM}=7.8±0.2; N = 3; **p<0.01 vs SHAM). SHAM = mice treated with vehicle (1% methyl cellulose); CUDRA = mice treated with cudraflavone B (25 mg/kg suspended in 1% methyl cellulose).



Figure 2. In vitro inhibitory response mediated by cudraflavone B on isolated ileal segments.

Panel A. Concentration-response curve to cudraflavone B (0.1-100 µM) in isolated mouse ileal preparations (N = 3). Data are expressed as percentage of the decrease in the amplitude of the spontaneous contraction. The value 100% corresponds to 75% reduction of spontaneous contractions. CNTR = isolated ileal segments in absence of cudraflavone B; CUDRA = isolated ileal segments treated with increasing concentrations of cudraflavone B. Panel B. Percentage of residual contraction at the higher concentration of cudraflavone B (100 μ M; N = 3). ***p<0.001 vs CNTR.

EFFECTS OF DIPLACONE ON SMALL INTESTINE CONTRACTILITY



Figure 3. Effects of diplacone on the ileum spontaneous contractility.

Panels A and B. Diplacone (100 μ M) does not alter the spontaneous contractility of ileum in frequency and amplitude (N = 4). CNTR = isolated ileal segments in absence of diplacone; DIPLA = isolated ileal segments pretreated with 100 μ M diplacone.

Figure 4. Effects of diplacone on the excitatory and inhibitory contractile responses.

Carbachol [log M]

Panel A. Effect of electrical field stimulation (EFS; 10 Hz) on the excitatory response of ileal segments in presence or absence of 100 µM diplacone pretreatment. Panels B and C. Concentration-response curves to carbachol (0.001-100 µM) and excitatory effect elicited by KCl 60 mM in ileum segments in presence or absence of 100 µM diplacone pretreatment. Panel D. Inhibitory response to isoprenaline (0.1 μ M) of ileal segments in presence or absence of 100 μ M diplacone pretreatment. (N = 4). *p<0.05; ***p<0.001 vs CNTR. CNTR = isolated ileal segments in absence of diplacone; DIPLA = isolated ileal segments pretreated with 100 μ M diplacone.

METHODS

- ✓ Diplacone was isolated from the unripe fruits of *Paulownia tomentosa* (Thunb.) Steud. (Paulowniaceae) as previously described (Vochyánová et al., 2015).
- Cudraflavone B was isolated from Morus alba L. (Moraceae) as previously described (Zelová et al., 2014).

Male mice C57BL/6J (8±1 weeks old; Charles River Laboratories, Italy) were used.

- In vitro contractility was assessed in full-thickness distal ileum segments isolated from control (CNTR) mice (N = 4), mounted vertically in organ baths containing 10 mL of oxygenated (95% O₂ and 5% CO₂) and heated (37°C) Krebs solution. Changes in muscle tension following carbachol (CCh; 0.01–100 µmol/L) or KCl (60 mmol/L) or isoprenaline (0.1 µmol/L) stimuli in presence or absence of pretreatment with diplacone (DIPLA; 100 μM) were recorded by isometric transducers. Neuronal-mediated contractions were evoked by electrical field stimulation (EFS; 10 Hz; 40 V). The effect was performed in presence of diplacone (DIPLA; 100 μM). In a second series of experiments concentration-response curve to cumulative addition of cudraflavone B (CUDRA, 0.1 µM-100 µM) was performed to assess changes in spontaneous contractility (Brun et al., 2013).
- ✓ Gastrointestinal transit was obtained by measuring the distribution of nonabsorbable fluorescein isothiocyanate labeled dextran (FITC-dextran, 70 KDa) from the stomach to the colon. A cudraflavone B sospension (25 mg/kg in 1% methyl cellulose) or a 1% methyl cellulose bolus was administered by gavage to CUDRA and SHAM mice, respectively, 2 hours before administering FITC-dextran. Each segment of the bowel of CUDRA and SHAM mice (N = 3) was examined separately and luminal contents was collected and clarified by centrifugation (12,000 rpm, 10 min, 4°C). Fluorescent intensity of the supernatant was measured at 492/521 nm using a fluorometer (Victor, PerkinElmer). Data were expressed as % of fluorescence per segment and gastrointestinal transit was calculated as the geometric center (GC) of distribution of the fluorescent probe (Brun et al., 2013).

REFERENCES

✓ Brun P, Giron MC et al. Gastroenterology. 2013; 145(6):1323-33.

- ✓ De Palma G, Collins SM, Bercik P. Gut Microbes. 2014; 5(3):419-29.
- ✓ Lee DS, Ko W et al. Molecules. 2014; 19(8):10818-31.
- ✓ Vochyánová Z, Bartošová L et al. Fitoterapia. 2015; 101:201-7.
- ✓ Zelová H, Hanáková Z et al. J Nat Prod. 2014;

77(6):1297-303.







unpaired Student's t-test or by one-way ANOVA followed by Newman-Keuls multiple comparison post-test. P values < 0.05 were considered statistically significant.